Lerner Research Institute News
Read about the latest advances from Lerner Research Institute scientists, including new findings, grant awards, innovations and collaborations.
Metformin identified as a potential atrial fibrillation treatment in collaborative research
How drugs and atrial fibrillation affect functions and genes in the body is the subject of a recent study into metformin and other candidate drugs.
Cleveland Clinic researchers have identified a common diabetes medication, metformin, as a possible treatment for atrial fibrillation.
The study, published in Cell Reports Medicine, built on ongoing collaborative Cleveland Clinic research to support further investigation into metformin as a drug repurposing candidate. Researchers used advanced computation and genetic sequencing to determine that metformin’s targets overlap significantly with genes dysregulated in atrial fibrillation.
Finding drugs or procedures to treat atrial fibrillation is tricky because of potential serious side effects, researchers noted in the study. New drugs for atrial fibrillation were last approved more than a decade ago, notes Mina Chung, MD, Department of Cardiovascular and Metabolic Sciences in the Lerner Research Institute, a senior author on the study.
“It's not that we've found a new drug target where it takes 20 years to test this in individuals,” says Jessica Castrillon Lal, the study’s first author and a fifth-year graduate student in the Cleveland Clinic Molecular Medicine program. “We can cut off 10 years in the drug approval pipeline. We already have the information there. We just have to test it in a very controlled way.”
The analysis found metformin targeted 30 genes associated with atrial fibrillation, with direct effects on gene expression for eight. Eight other candidate drugs surfaced in the analysis, but researchers were able to identify metformin as the most-promising candidate through testing and reviewing outcomes in large stores of patient data.
Castrillon Lal conducts research at the Genomic Medicine Institute. The lab led by Feixiong Cheng, PhD, uses network medicine approaches to find candidate drugs for repurposing, creating vast networks of molecular interactions. For this study, researchers winnowed down a list of 2,800 FDA-approved treatments by analyzing three data sources: a map of interactions between proteins called an “interactome”; a network of genes associated with atrial fibrillation; and each medicine’s molecular or genetic targets.
Decoding atrial fibrillation
Atrial fibrillation is the most common type of heart arrhythmia in the world and can lead to complications, including stroke and heart failure. Treatments have been primarily directed toward trying to prevent the arrhythmia using drugs targeting the electrical system, including ion channels in the heart, or using catheter ablation to isolate the pulmonary veins where initiating beats of atrial fibrillation occur.
However, side effects, limited success and potential complications can limit these approaches.
The research was conducted in Dr. Chung’s lab in the Department of Cardiovascular and Metabolic Sciences, in collaboration with labs led by Dr. Cheng; David Van Wagoner, PhD; Jonathan Smith, PhD, Department of Cardiovascular and Metabolic Sciences; and John Barnard, PhD, Department of Quantitative Health Sciences in the Lerner Research Institute.
Prior work from Drs. Chung, Smith, Van Wagoner and Barnard had also identified the enzyme AMPK as a potential key regulator for metabolic stress. Metabolic stress has been associated with atrial fibrillation.
This work is related to a $14.2 million grant from NIH to investigate new atrial fibrillation treatments using genomic data. Researchers further supported results of the network analyses with experiments on live beating heart cells grown from human stem cells, showing favorable effects of metformin on gene expression.